The Efficacy of Subconjunctival Bevacizumab in Diabetic Macular Edema
Not Applicable
Completed
- Conditions
- Diabetic Macular Edema
- Interventions
- Drug: Subconjunctival bevacizumab (Altuzan)
- Registration Number
- NCT02796183
- Lead Sponsor
- Neon Hospital
- Brief Summary
This study evaluates the effects of subconjunctivally injected bevacizumab in patients with diffuse diabetic macular edema.
- Detailed Description
At baseline, the macular thicknesses of both eyes of the patients with persistant diabetic macular edema were measured by optical coherence tomography. After 3.75mg bevacizumab was injected into subconjunctival space of the eyes with diabetic macular edema. The measurements of the macular thicknesses were repeated by optical coherence tomography in 15th, 30th, 60th day after injections. The macular thickness measurements before and after injection were compared.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
- Having diffuse diabetic macular edema persisted at least 1 month
- No intravitreal injection in last 3 months.
- No retinal laser photocoagulation in last 6 months
- Not have any other macular disease causing macular edema
Exclusion Criteria
- Having ischemic macula
- Intravitreal injection in last 3 months.
- Retinal laser photocoagulation in last 6 months
- Have any other macular disease causing macular edema
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Diabetic macular edema Subconjunctival bevacizumab (Altuzan) Bevacizumab (Altuzan) was injected subconjunctival space of the patients.
- Primary Outcome Measures
Name Time Method Central Macular Thickness one year (between May 2015 and May 2016)
- Secondary Outcome Measures
Name Time Method